Skip to main content

Table 2 Prediction for infection

From: One-year mortality and Periprosthetic infection rates after Total knee Arthroplasty in Cancer patients: a population-based cohort study

  Crude Adjusted
sHRa(95%C.I.) p-value sHRa(95%C.I.) p-value
Cancer vs. Non-cancer 0.92 (0.64–1.32) 0.6374 0.91 (0.63–1.31) 0.6089
Comorbidities
 Myocardial infarct 1.58 (0.74–3.36) 0.2355 1.47 (0.68–3.18) 0.3334
 congestive heart failure 1.18 (0.77–1.79) 0.4473 1.07 (0.70–1.64) 0.7466
 peripheral vascular 1.42 (0.73–2.78) 0.3036 1.33 (0.68–2.63) 0.4084
 cerebrovascular disease 1.22 (0.87–1.69) 0.2500 1.08 (0.76–1.53) 0.6857
 dementia 1.79 (0.92–3.51) 0.0874 1.63 (0.82–3.24) 0.1631
 chronic lung disease 1.17 (0.88–1.55) 0.2827 1.11 (0.82–1.50) 0.4975
 connective tissue disease 1.06 (0.63–1.80) 0.8218 1.05 (0.62–1.78) 0.8579
 Ulcer 1.10 (0.83–1.46) 0.5153 1.03 (0.77–1.38) 0.8437
 chronic liver disease 1.09 (0.75–1.59) 0.6491 1.07 (0.73–1.57) 0.7438
 Diabetes 1.14 (0.84–1.54) 0.4175 0.99 (0.71–1.40) 0.9698
 diabetes with end organ damage 1.77 (1.03–3.06) 0.0401 1.67 (0.91–3.06) 0.1007
 Hemiplegia 1.52 (0.48–4.80) 0.4733 1.28 (0.40–4.12) 0.6779
 moderate or severe kidney disease 1.12 (0.67–1.87) 0.6631 1.07 (0.64–1.79) 0.7902
 Moderate or severe liver disease   
 AIDS .-   
 Chemotherapy 0.96 (0.54–1.72) 0.8913 0.99 (0.47–2.09) 0.9815
 Metastasis 8.66 (1.24–60.50) 0.0296 10.13 (1.19–86.34) 0.0343
  1. sHRa: subdistribution hazard ratio